Atea Pharmaceuticals, Inc. Operating Expenses
Atea Pharmaceuticals, Inc. (AVIR) reported Operating Expenses of $35.10 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-12
- Atea Pharmaceuticals, Inc. operating expenses for the quarter ending 2026-06-30 was $35.10M, a 15.11% decline year-over-year.
- Atea Pharmaceuticals, Inc. operating expenses for the quarter ending 2026-03-31 was $48.01M, a 22.97% increase year-over-year.
- Atea Pharmaceuticals, Inc. operating expenses for the quarter ending 2025-12-31 was $54.93M, a 40.76% increase year-over-year.
- Atea Pharmaceuticals, Inc. operating expenses for the quarter ending 2025-09-30 was $45.57M, a 22.49% increase year-over-year.
- Atea Pharmaceuticals, Inc. operating expenses for fiscal 2025 was $180.89M, a 6.25% decline from fiscal 2024.
- Atea Pharmaceuticals, Inc. operating expenses for fiscal 2024 was $192.95M, a 17.54% increase from fiscal 2023.
- Atea Pharmaceuticals, Inc. operating expenses for fiscal 2023 was $164.16M, a 25.65% increase from fiscal 2022.
- Atea Pharmaceuticals, Inc. operating expenses for fiscal 2022 was $130.65M, a 38.66% decline from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $35.10M 10-Q · filed 2026-08-12 | $83.11M 10-Q · filed 2026-08-12 | $138.04M derived: sum of 3 quarters · filed 2026-08-12 | $183.61M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $48.01M 10-Q · filed 2026-05-12 | $102.94M derived: sum of 2 quarters · filed 2026-05-12 | $148.51M derived: sum of 3 quarters · filed 2026-05-12 | $189.85M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $54.93M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $100.50M derived: sum of 2 quarters · filed 2026-03-05 | $141.85M derived: sum of 3 quarters · filed 2026-08-12 | $180.89M 10-K · filed 2026-03-05 |
| 2025-09-30 | $45.57M 10-Q · filed 2025-11-12 | $86.91M derived: sum of 2 quarters · filed 2026-08-12 | $125.95M 10-Q · filed 2025-11-12 | $164.98M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $41.34M 10-Q · filed 2026-08-12 | $80.39M 10-Q · filed 2026-08-12 | $119.41M derived: sum of 3 quarters · filed 2026-08-12 | $156.61M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $39.04M 10-Q · filed 2026-05-12 | $78.07M derived: sum of 2 quarters · filed 2026-05-12 | $115.27M derived: sum of 3 quarters · filed 2026-05-12 | $162.19M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $39.03M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $76.23M derived: sum of 2 quarters · filed 2026-03-05 | $123.14M derived: sum of 3 quarters · filed 2026-03-05 | $192.95M 10-K · filed 2026-03-05 |
| 2024-09-30 | $37.20M 10-Q · filed 2025-11-12 | $84.12M derived: sum of 2 quarters · filed 2025-11-12 | $153.92M 10-Q · filed 2025-11-12 | $200.50M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $46.92M 10-Q · filed 2025-08-07 | $116.72M 10-Q · filed 2025-08-07 | $163.29M derived: sum of 3 quarters · filed 2025-08-07 | $204.08M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $69.81M 10-Q · filed 2025-05-12 | $116.38M derived: sum of 2 quarters · filed 2025-05-12 | $157.16M derived: sum of 3 quarters · filed 2025-05-12 | $192.40M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $46.57M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $87.36M derived: sum of 2 quarters · filed 2025-03-06 | $122.59M derived: sum of 3 quarters · filed 2025-03-06 | $164.16M 10-K · filed 2025-03-06 |
| 2023-09-30 | $40.78M 10-Q · filed 2024-11-07 | $76.02M derived: sum of 2 quarters · filed 2024-11-07 | $117.59M 10-Q · filed 2024-11-07 | $157.49M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $35.23M 10-Q · filed 2024-08-07 | $76.80M 10-Q · filed 2024-08-07 | $116.70M derived: sum of 3 quarters · filed 2024-08-07 | $132.98M derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | $41.57M 10-Q · filed 2024-05-14 | $81.47M derived: sum of 2 quarters · filed 2024-05-14 | $97.75M derived: sum of 3 quarters · filed 2024-05-14 | $130.04M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $39.90M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $56.18M derived: sum of 2 quarters · filed 2024-02-28 | $88.47M derived: sum of 3 quarters · filed 2024-02-28 | $130.65M 10-K · filed 2024-02-28 |
| 2022-09-30 | $16.28M 10-Q · filed 2023-11-08 | $48.58M derived: sum of 2 quarters · filed 2023-11-08 | $90.75M 10-Q · filed 2023-11-08 | $161.75M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $32.30M 10-Q · filed 2023-08-08 | $74.47M 10-Q · filed 2023-08-08 | $145.47M derived: sum of 3 quarters · filed 2023-08-08 | $200.43M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $42.17M 10-Q · filed 2023-05-08 | $113.17M derived: sum of 2 quarters · filed 2023-05-08 | $168.13M derived: sum of 3 quarters · filed 2023-05-08 | $219.84M derived: sum of 4 quarters · filed 2023-05-08 |
| 2021-12-31 | $71.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $125.96M derived: sum of 2 quarters · filed 2023-02-28 | $177.66M derived: sum of 3 quarters · filed 2023-02-28 | $212.99M 10-K · filed 2023-02-28 |
| 2021-09-30 | $54.96M 10-Q · filed 2022-11-07 | $106.66M derived: sum of 2 quarters · filed 2022-11-07 | $141.99M 10-Q · filed 2022-11-07 | $169.98M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $51.70M 10-Q · filed 2022-08-08 | $87.03M 10-Q · filed 2022-08-08 | $115.02M derived: sum of 3 quarters · filed 2023-02-28 | $132.65M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $35.33M 10-Q · filed 2022-05-10 | $63.32M derived: sum of 2 quarters · filed 2023-02-28 | $80.94M derived: sum of 3 quarters · filed 2023-02-28 | $90.95M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $27.99M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $45.62M derived: sum of 2 quarters · filed 2023-02-28 | $55.62M derived: sum of 3 quarters · filed 2023-02-28 | $59.66M 10-K · filed 2023-02-28 |
| 2020-09-30 | $17.63M 10-Q · filed 2021-11-12 | $27.63M derived: sum of 2 quarters · filed 2021-11-12 | $31.68M 10-Q · filed 2021-11-12 | $36.43M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $10.00M 10-Q · filed 2021-08-12 | $14.05M 10-Q · filed 2021-08-12 | $18.80M derived: sum of 3 quarters · filed 2022-02-28 | $22.57M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $4.04M 10-Q · filed 2021-05-13 | $8.79M derived: sum of 2 quarters · filed 2022-02-28 | $12.56M derived: sum of 3 quarters · filed 2022-02-28 | |
| 2019-12-31 | $4.75M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $8.52M derived: sum of 2 quarters · filed 2022-02-28 | $14.61M 10-K · filed 2022-02-28 | |
| 2019-09-30 | $3.77M 10-Q · filed 2020-12-10 | $9.86M 10-Q · filed 2020-12-10 | ||
| 2018-12-31 | $9.48M 10-K · filed 2021-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |